Triple

T1169411
Position Surface form Disambiguated ID Type / Status
Subject Spinraza E24879 entity
Predicate targetsGene P24557 FINISHED
Object SMN2
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
E24879 NE FINISHED

How this triple was built (5 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: SMN2 | Statement: [Spinraza, targetsGene, SMN2]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: SMN2
Context triple: [Spinraza, targetsGene, SMN2]
  • A. spinal muscular atrophy
    Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
  • B. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • C. DEL2
    DEL2 is Germany’s second-tier professional ice hockey league, sitting directly below the top-level DEL.
  • D. Protogeneia
    Protogeneia is a figure in Greek mythology, traditionally regarded as the daughter of Deucalion and Pyrrha and associated with the earliest generations of humankind after the great flood.
  • E. Hipple
    Hipple is the birth surname of American film and television actor Hugh Marlowe.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: SMN2
Triple: [Spinraza, targetsGene, SMN2]
Generated description
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: SMN2
Target entity description: SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
  • A. spinal muscular atrophy
    Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
  • B. Spinraza chosen
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • C. DEL2
    DEL2 is Germany’s second-tier professional ice hockey league, sitting directly below the top-level DEL.
  • D. Protogeneia
    Protogeneia is a figure in Greek mythology, traditionally regarded as the daughter of Deucalion and Pyrrha and associated with the earliest generations of humankind after the great flood.
  • E. Hipple
    Hipple is the birth surname of American film and television actor Hugh Marlowe.
  • F. None of above.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: targetsGene
Context triple: [Spinraza, targetsGene, SMN2]
  • A. target
    Indicates that one entity is the intended object, goal, or focus of another entity’s action or attention.
  • B. regulatoryInteraction
    Indicates a relationship where one entity modulates, controls, or influences the activity, expression, or function of another entity through regulatory mechanisms.
  • C. hasTargetDisease
    Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
  • D. targetsGroup
    Indicates that an action, influence, or effect is directed toward a specific group as its intended recipient or focus.
  • E. geneticInfluence
    Indicates that one entity affects or contributes to the genetic traits, characteristics, or heredity of another entity.
  • F. None of above. chosen

Provenance (7 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac668562788190ac5f8d081a46b2ee completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac67a07f28819096fcd7b767e07a63 completed March 7, 2026, 6 p.m.
NED2 Entity disambiguation (via description) batch_69ac6826ef4c81909fc077bfba22b16f completed March 7, 2026, 6:02 p.m.
PD Predicate disambiguation batch_69a4bb5656948190b0b1d5446ad06005 completed March 1, 2026, 10:19 p.m.
PDg Predicate description generation batch_69a4bbd7ff1881908c943ecdfea59e81 completed March 1, 2026, 10:21 p.m.
Created at: March 1, 2026, 7:45 p.m.